Disease detection and monitoring company Glympse Bio has raised $ 22 m in series A funding towards developing its in urine sensing technology . The Cambridge , Massachusetts - based firm is creating technology that can be delivered to the area of diseased tissue in urine , where it can examine the area 's biological activity before emitting a signal that can be transmitted through urine . The company is currently focusing on non - alcoholic steatohepatitis , or NASH , which can lead to cirrhosis of the liver . The funding round was led by ARCH Ventures and LS Polaris Innovation Fund .
Disease detection and monitoring company Glympse Bio has raised $22m in series A funding towards developing its in vivo sensing technology. The Cambridge, Massachusetts-based firm is creating technology that can be delivered to the area of diseased tissue in patients, where it can examine the area's biological activity before emitting a signal that can be detected through urine. The company is currently focusing on non-alcoholic steatohepatitis, or NASH, which can lead to cirrhosis of the liver. The funding round was led by ARCH Ventures and LS Polaris Innovation Fund.